Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient
Open Access
- 1 November 2000
- journal article
- case report
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 26 (9) , 1021-1024
- https://doi.org/10.1038/sj.bmt.1702593
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a complication of allogeneic bone marrow transplantation (BMT). Rare cases of PTLD after autologous BMT have been reported only in adults. This case report is the first to describe PTLD in a pediatric patient after autologous peripheral stem cell transplantation (PSCT). This 2-year-old male with stage IV neuroblastoma underwent autologous PSCT. The post-PSCT course was complicated by fever with hematochezia and a lung mass. On day 94 post PSCT, colonoscopy revealed an ulcer due to a PTLD, monomorphic type, B cell phenotype, associated with Epstein–Barr virus. Fine needle aspiration identified the lung mass as neuroblastoma. PTLD can occur in pediatric autologous PSCT recipients, and may occur more frequently in autologous grafts manipulated by T cell depletion or CD34+ cell selection. Bone Marrow Transplantation (2000) 26, 1021–1024.Keywords
This publication has 14 references indexed in Scilit:
- Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell TransplantationBlood, 1999
- A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantationBone Marrow Transplantation, 1998
- Epstein–Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two casesBone Marrow Transplantation, 1998
- Epstein‐Barr virus associated B‐cell lymphoma after autologous bone marrow transplantation for T‐cell acute lymphoblastic leukaemiaBritish Journal of Haematology, 1997
- Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features.American Journal of Clinical Pathology, 1997
- Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationThe Lancet, 1995
- Infusions of Donor Leukocytes to Treat Epstein-Barr Virus-Associated Lymphoproliferative Disorders after Allogeneic Bone Marrow TransplantationNew England Journal of Medicine, 1994
- EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER FOLLOWING AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR NON-HODGKINʼS LYMPHOMATransplantation, 1993
- T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complicationsBlood, 1990
- Expression of Epstein–Barr Virus Transformation–Associated Genes in Tissues of Patients with EBV Lymphoproliferative DiseaseNew England Journal of Medicine, 1989